Primary ADT ineffective for most men with early stage prostate cancer

Data from a large, retrospective study, reported in the Journal of Clinical Oncology, suggest something that many expert clinicians and patients have long suspected … that early use of androgen deprivation therapy (ADT) alone is not an effective treatment for most men with early stage prostate cancer. … READ MORE …

Supervised exercise and prevention of ADT-related side effects

A small, randomized trial in a group of 60+ Australian patients has demonstrated that a supervised exercise program started at the same time as initiation of androgen deprivation therapy (ADT) can have multiple beneficial results, including (at least temporary) avoidance of known side effects of ADT. … READ MORE …

Quality of life in the first 2 years on ADT for non-metastatic patients

A forthcoming paper in the Journal of Urology has attempted to quantify the effects of androgen deprivation therapy (ADT) on the mental and emotional well-being of men with non-metastatic prostate cancer. … READ MORE …

Surprise: exercise is good for men on ADT!

According to a review article recently published in the Journal of Clinical Oncology, “Among patients … treated with androgen-deprivation therapy, appropriately prescribed exercise is safe and may ameliorate a range of treatment-induced adverse effects.” … READ MORE …

Early docetaxel chemotherapy + ADT extends survival of men with metastatic prostate cancer

According to a media release issued yesterday by the National Institutes of Health, the CHAARTED clinical trial has shown that men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone. … READ MORE …

10-year data from RTOG 9910 endorses 8 weeks of neoadjuvant ADT prior to radiation

According to a report on Practice Update last Monday, some interesting data were presented at a plenary session at the annual meeting of the American Society for Radiation Oncology (ASTRO) based on 10-year follow-up of men in the RTOG 9910 trial. … READ MORE …

Prevention of bone-related and metabolic complications of treatment for men on ADT

A new article from an Australian clinical research group in the journal Andrology addresses “the effectiveness of implementing standardized guidelines to mitigate metabolic and bone side effects of androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer.” … READ MORE …

Radiation therapy, neoadjuvant ADT, and initial PSA response

New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer. … READ MORE …

Australian researchers identify “castration-tolerant cancer-repopulating cells” in mouse model

According to a media release issued earlier today in Australia, “a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments.” … READ MORE …

Sipuleucel-T before or after ADT in men with biochemically recurrent disease?

A paper to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is entitled, “A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results.” … READ MORE …

Expert opinion on ADT for CRPC today

As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used to. … READ MORE …

First-line enzalutamide in high-risk, ADT-naive patients (including those with metastatic disease)

According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). … READ MORE …

Abiraterone acetate for men with metastatic disease and a sub-optimal response to ADT

The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …

New Phase III trial is testing ADT + bicalutamide vs. ADT + TAK-700

It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …

New meta-analysis endorses IADT for good responders to initial CADT

A new meta-analysis of data from nine large clinical trials suggests that, “There is fair evidence to recommend use of [intermittent] instead of [continuous androgen deprivation] for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers